Company Overview

SCYNEXIS, Inc. is a U.S.-based biotechnology company focused on the discovery, development, and commercialization of antifungal therapies for difficult-to-treat and drug-resistant fungal infections. The company operates within the biopharmaceutical and infectious disease sectors, with a strategic emphasis on novel anti-infective agents targeting invasive and recurrent fungal diseases. Its primary commercial and clinical focus has centered on ibrexafungerp, a triterpenoid antifungal agent marketed under the brand BREXAFEMME for vulvovaginal candidiasis and investigated for additional invasive fungal indications.

The company was founded in 1999 and is headquartered in Jersey City, New Jersey. SCYNEXIS evolved from an early-stage anti-infectives research company into a clinical-stage biotechnology firm specializing in antifungal therapeutics. A key strategic differentiator is its proprietary glucan synthase inhibitor platform, which differs structurally from echinocandin antifungals and is designed to provide oral and intravenous treatment options against resistant fungal pathogens. The company’s activities have included licensing, clinical development partnerships, and intellectual property monetization tied to antifungal assets.

Business Operations

SCYNEXIS primarily generates value through the development, licensing, and commercialization of antifungal compounds, particularly ibrexafungerp. Historically, operations have included product sales, licensing agreements, milestone payments, and collaboration revenue associated with commercialization partners. The company’s principal operating activities have been concentrated in research and development, regulatory advancement, and lifecycle management of antifungal candidates. Its business model has relied heavily on strategic partnerships to support commercialization and global development efforts.

A major component of SCYNEXIS’s operations has involved collaborations with external pharmaceutical organizations. The company previously entered commercialization and licensing arrangements involving BREXAFEMME and related ibrexafungerp rights in certain territories. SCYNEXIS has also maintained intellectual property assets covering triterpenoid antifungal compounds and formulations. Operations are primarily U.S.-based, though the company has pursued international regulatory and commercial opportunities through partnership structures rather than extensive direct overseas infrastructure.

Strategic Position & Investments

SCYNEXIS has positioned itself as a specialist antifungal developer targeting areas of unmet medical need, including azole-resistant and multidrug-resistant fungal infections. Strategic priorities have included expanding the clinical utility of ibrexafungerp beyond vulvovaginal candidiasis into invasive candidiasis and other serious fungal indications. The company has invested substantially in clinical development programs, regulatory submissions, and intellectual property protections intended to support long-term antifungal franchise value.

The company has also pursued strategic restructuring and financing initiatives to preserve liquidity and extend operational runway amid evolving clinical and regulatory developments. SCYNEXIS has historically partnered with larger pharmaceutical organizations to support commercialization and market expansion. Its broader strategic relevance within biotechnology stems from increasing global concern over antimicrobial resistance and limited innovation in systemic antifungal therapeutics. Public filings and investor disclosures indicate continued emphasis on leveraging proprietary antifungal chemistry platforms and maximizing the value of existing development assets.

Geographic Footprint

SCYNEXIS is headquartered in Jersey City, New Jersey, and its primary operational footprint is concentrated in the United States. The company’s commercial, clinical, and regulatory activities have largely focused on the U.S. market, including interactions with the U.S. Food and Drug Administration and domestic commercialization initiatives. Research and corporate functions are managed through its U.S.-based operations.

Internationally, SCYNEXIS has pursued market exposure through licensing arrangements, collaborative development structures, and regulatory engagement in selected foreign jurisdictions. The company’s antifungal development programs have had relevance across North America, Europe, and certain other international markets due to the global prevalence of resistant fungal infections. While SCYNEXIS does not maintain a broad multinational operational infrastructure comparable to large pharmaceutical firms, its intellectual property portfolio and partnership strategy have provided international commercial reach.

Leadership & Governance

SCYNEXIS leadership has emphasized disciplined capital management, targeted antifungal innovation, and strategic partnering within the biotechnology sector. Governance and operational direction are overseen by an executive leadership team and board with backgrounds in pharmaceuticals, clinical development, finance, and biotechnology commercialization. Public company disclosures indicate continued focus on preserving shareholder value while advancing differentiated anti-infective assets.

Key executives and leadership figures include:

• David J. Angulo, M.D. – President and Chief Executive Officer
• Michael J. Leland – Chief Financial Officer
• Marco Taglietti, M.D. – Former President and Chief Executive Officer
• Ramin “Ron” Farhangi – Chair of the Board of Directors

Information summarized above is consistent with disclosures in SEC filings, company investor materials, and reporting from major financial and biotechnology industry publications. Some partnership and commercialization arrangements have evolved over time; where details differ across reporting periods, the most recent publicly available company disclosures were prioritized.